Diaceutics Plc · LSE:DXRX
Diaceutics — Investor Presentation (February 2026)
18 slides from Diaceutics's investor presentation, February 2026
Slide 1: Better Testing, Better Treatment
Better Testing, Better Treatment Corporate Overview – January / February 2026 Ryan Keeling | Chief Executive Officer | [email protected] Nick Roberts | Chief Financial Officer | [email protected] 1 © copyright Diaceutics 2024 2025 Permission must be sought from Diaceutics if you
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Disclaimer and Forward-Looking Statements Disclaimer : The information provided in this presentation is for the sole use of those attending the presentation This presentation has been prepared by Diaceutics the (“Company”). “Presentation” means this document
Slide 3: FY 2025 Highlights
FY 2025 Highlights FY 2025 Highlights • Reported revenues expected to be £38.5 million, representing 20% growth and a return to profitability • Revenue on a constant currency basis expected to show 24% growth in line with analyst consensus estimates* • FY 2025 Adjusted EBITDA** expected to exceed an
Slide 4: FY 2025 Operational Dashboard
FY 2025 Operational Dashboard FY 2025 Operational Dashboard 10 enterprise-wide 212 people inc. 95 therapeutic 53 active engagements new US sales brands customers ARR £13.0m team expansion ($17.2m) Up from 7 and 199 at Dec-24 Up from 85 in Up on 52 in £10.6m ($13.5m) 2024 2024 at Dec-24 PMx Commercia
Slide 5: Financial Strength
Financial Strength Financial Strength Ability to deliver exceptionally high margins through operational leverage – shift to profitability in FY 2025 Revenue CAGR 25% over past 3 years Growing ARR revenues and future revenue visibility Ten enterprise-wide engagements with blue-chip customers driving
Slide 6: FY 2025 Financial Dashboard
FY 2025 Financial Dashboard FY 2025 Financial Dashboard Revenue ARR Order book value Adjusted EBITDA £38.5m £20.3m £36.8m £7.1m Up 20% and 25% Up 21% and 30% on Up 48% Analyst on a CC basis a CC basis consensus CAGR of 25% over estimate 3 yrs from £32.2m from £16.8m from £24.9m from £4.2m in 2024 at
Slide 7: We help pharma find patients - 3 unique assets
We help pharma find patients - 3 unique assets We help pharma find patients - 3 unique assets 1. Lab network 2. Data 3. DXRX Platform Global network of World’s largest World’s first diagnostic labs repository of commercialisation platform for healthcare data precision medicine Pharma Labs Physicians
Slide 8: What we do - A DXRX Signal Case Study
What we do - A DXRX Signal Case Study What we do - A DXRX Signal Case Study The result: The situation: increase in patients Client ROI: A pharma client needed to locate Upon switching on DXRX Signal in Each patient worth an average revenue of patients with a specific lung cancer week 27 of year 1 th
Slide 9: What is Precision Medicine?
What is Precision Medicine? What is Precision Medicine? Precision Medicine (PM) is the tailoring of medical treatment to the individual characteristics of each patient – a patient’s unique genetic profile makes them susceptible to certain diseases and can influence which treatments will be safe and
Slide 10: The Precision Medicine Challenge
The Precision Medicine Challenge The Precision Medicine Challenge PM drugs are With new PM drugs typically PM drugs are highly inherently actionable have a smaller efficacious, but it dependent on their biomarkers entering patient population, can be challenging diagnostic pathway the market making p
Slide 11: Powered by our DXRX Platform - PMx Supercharges our Commercialisation Solution for Biopharma
Powered by our DXRX Platform - PMx Supercharges our Commercialisation Solution for Biopharma Powered by our DXRX Platform - PMx Supercharges our Commercialisation Solution for Biopharma Launched in 2022, Signal Launched in 2024, PMx enables Biopharma sales supercharges the impact of signal team to f
Slide 12: PMx Enables us to Unlock Greater Value for Biopharma and Take a Larger Share of this Value
PMx Enables us to Unlock Greater Value for Biopharma and Take a Larger Share of this Value PMx Enables us to Unlock Greater Value for Biopharma and Take a Larger Share of this Value PMx can potentially increase annual revenue per therapeutic brand •from V £0.4m to £3m+ Expanding our share of the Evo
Slide 13: Significant & Growing Market Opportunity
Significant Growing Market Opportunity Significant & Growing Market Opportunity Incremental Opportunity Current Status INCREASE PENETRATION IN EXISTING MARKET TAM $645m Progressing to plan Actively upsell solutions to new and existing brands within the 3-year revenue CAGR 25% core precision medicine
Slide 14: PMx Integrates our Full Commercialisation Toolkit
PMx Integrates our Full Commercialisation Toolkit PMx Integrates our Full Commercialisation Toolkit Understand Strategy Strategy Tracking Adoption the market development implementation Understand uptake Drive precision Data products Professional Scientific & medicine therapy and conversion to & prof
Slide 15: Moving the Needle for our Customers
Moving the Needle for our Customers Moving the Needle for our Customers Delivering customer-centric excellence is critical to our strategy. This year we have achieved a 3.7/4 satisfaction score, with customers providing the following snippets of feedback: “One of our most important business “Diaceut
Slide 16: Industry Leaders in Diagnostic Commercialisation
Industry Leaders in Diagnostic Commercialisation Industry Leaders in Diagnostic Commercialisation RYAN KEELING SARAH BONDI MARIANNA SCIORTINO Chief Executive Officer & VP Sales VP Data Partnerships & Strategy Co-Founder NICK ROBERTS KEVIN ENTWISTLE MADELINE BROWN Chief Financial Officer VP Advisory
Slide 17: Helping Pharma Find Patients
Helping Pharma Find Patients Helping Pharma Significant & Growing Market Opportunity Find Patients Global pharma rapidly shifting to precision medicine to target better patient care, capture lost revenue and increase profitability Growth Driven by Customer Success Strong Competitive Compelling Finan
Slide 18: Team & Contacts
Team Contacts Team & Contacts Ryan Keeling Nick Roberts Chief Executive Officer Chief Financial Officer [email protected] Hayley Palmer | Canaccord Genuity | [email protected] Julie Simmonds | Panmure Liberum | [email protected] Natalia Webster | RBC Capital Markets | na